The FDA decision extends Purdue Pharma LP's patent protection of OxyContin for at least another year, if not much longer. The blockbuster pain drug racked up sales of $2.8 billion last year, according to IMS Health Inc. By blocking generic entrants, the FDA is signaling to the broader painkiller industry that it will reward companies that produce drugs with such safeguards.